Chairman of the Board
Elmar Schnee, is the Chairman of the Board of Directors of Calliditas Therapeutics AB. He was previously CEO of Merck Serono and was instrumental in the acquisition of Serono by Merck KGaA. He has also served as General Partner and member of the Executive Board of Merck KGaA and has held previously several senior global management positions with UCB and Sanofi.
Renee Aguiar-Lucander, is the Chief Executive Officer of Calliditas Therapeutics AB. Before joining Calliditas, she was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Before that, she served as a Partner in the venture capital group 3i Group plc in London, where she managed the publicly quoted assets and was co-head of the global healthcare and technology portfolio. Prior to this, Renée Aguiar-Lucander was the European Group Head and Managing Director at a global investment bank and has more than 12 years’ experience in corporate finance. Prior to her career in investment banking, she was the Head of European Sales and Marketing in a company focused on the sale of software for financial services.
Jonathan A. Schur
Jonathan A. Schur, J.D., is the Group General Counsel of Calliditas Therapeutics AB. Prior to joining Calliditas in October 2020, Mr. Schur was in private practice, specializing in corporate, transactional and regulatory matters for pharmaceutical companies. He was a partner at Goodwin Procter LLP from May 2018 to September 2020, at Dechert LLP from February 2000 to April 2018, and at Hughes Hubbard and Reed LLP from January 1986 to January 2000. Mr. Schur received a J.D. from Harvard Law School and an A.B. from Harvard College. He is a member of the New York Bar and a former member of the Paris Bar.
Ilias (Elias) Papatheodorou
Mr. Elias Papatheodorou brings with him more than 20 years of experience with private and public biotechnology companies, as well as with The Coca-Cola Company and Philip Morris International. As Chief Business Officer of Covagen AG, he was instrumental in the closing of a CHF46 million Series B financing round and the subsequent acquisition of Covagen by Jannsen Pharmaceuticals, a J&J Company. Previously, Elias was Senior Vice President for Operations and Business Development at Medigene AG. Elias has also served for a number of years as the CEO of Novosom AG. During his tenure, the Smarticles technology entered clinical trials in the U.S.A., the company raised funds and closed licensing deals. Finally, he engineered the sale of Novosom's assets to Marina Biotech (MRNA). He received his undergraduate education at Ithaca College, NY, and his graduate education at Cornell University, NY.